Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: A new therapeutic approach for immune disorders

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 5B, 2008, Pages 1830-1847

  Anderson, Per ^a   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Autoimmunity; Inflammation; Lipid mediators; Lipoxins; Neuropeptide; Regulatory T cells; Resolvins; Tolerance

Indexed keywords

ANTIINFLAMMATORY AGENT; ICOSANOID; LIPOXIN; NEUROPEPTIDE;

AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPATHOLOGY; INFLAMMATION; REVIEW; TH1 CELL;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; EICOSANOIDS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; INFLAMMATION; LIPOXINS; MODELS, IMMUNOLOGICAL; NEUROPEPTIDES; TH1 CELLS;

EID: 55149111361     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00387.x     Document Type: Review

References (188)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003 423 : 356 61.
2. Goodnow CC. Multistep pathogenesis of autoimmune diseases. Cell. 2007 130 : 25 35.
3. Nathan C. Points of control in inflammation. Nature. 2002 : 420 : 846 52.
4. Mills KHG. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol. 2004 4 : 841 55.
5. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005 5 : 343 9.
6. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med. 2004 200 : 277 85.
7. + T-cells from patients with type 1 diabetes. Diabetes. 2005 54 : 92 9.
8. + regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 199 : 971 9.
9. Wan YY, Favell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev. 2006 212 : 114 30.
10. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol. 2007 7 : 52 63.
11. Gonzalez-Rey E, Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci. 2007 28 : 482 91.
12. Ariel A, Serhan CN. Resolvins and pro-tectins in the termination program of acute inflammation. Trends Immunol. 2007 28 : 176 83.
13. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004 3 : 401 16.
14. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008 3 : 279 312.
15. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008 153 : S200 15.
16. Blalock JE. The immune system as the sixth sense. J Intern Med. 2005 257 : 126 38.
17. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. 2006 6 : 318 28.
18. Molina PE. Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness. J Intern Med. 2006 259 : 138 54.
19. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970 169 : 1217 18.
20. Hadley ME, Haskell-Luevano C. The proopiomelanocortin system. Ann NY Acad Sci. 1999 885 : 1 21.
21. Oki Y, Sasano H. Localization and physiological roles of urocortin. Peptides. 2004 25 : 1745 9.
22. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000 21 : 138 67.
23. Spier AD, De Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Rev. 2000 33 : 228 41.
24. Van Der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, patho-physiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004 25 : 426 57.
25. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004 56 : 249 90.
26. Delgado M, Ganea D. Cutting Edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol. 2001 166 : 2907 12.
27. Blalock JE. Proopiomelanocortin and the immune-neuroendocrine connection. Ann NY Acad Sci 1999 885 : 161 72.
28. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today. 1997 18 : 140 5.
29. Gravanis A, Margioris AN. The corti-cotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem. 2005 12 : 1503 12.
30. Kubo A, Minamino N, Isumi Y, Katafuchi T, Kangawa K, Dohi K, Matsuo H. Production of adrenomedullin in macrophage cell line and peritoneal macrophage. J Biol Chem. 1998 273 : 16730 8.
31. Dalm VA. Cortistatin rather than somato-statin as a potential endogenous ligand for somatostatin receptors in the human immune system. J Clin Endocrinol Metab. 2003 88 : 270 6.
32. Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med. 2003 9 : 211 7.
33. Neumann Andersen G, Nagaeva O, Mandrika I, Petrovska R, Muceniece R, Mincheva-Nilsson L, Wikberg JE. MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions. Clin Exp Immunol. 2001 126 : 441 6.
34. Becher E, Mahnke K, Brzoska T, Kalden DH, Grabbe S, Luger TA. Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Ann NY Acad Sci. 1999 885 : 188 95.
35. Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Ichiyama T, Catania A, Lipton JM. Alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages. Am J Physiol. 1999 276 : R1289 94.
36. Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. The neuropeptide alpha-MSH has specific receptors on neu-trophils and reduces chemotaxis in vitro. Peptides. 1996 17 : 675 9.
37. Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti M. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol. 1999 162 : 7446 53.
38. Dalm VA. Expression of somatostatin cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003 285 : E344 53.
39. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW Jr., Taub DD. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004 114 : 57 66.
40. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002 54 : 233 46.
41. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 2003 55 : 21 6.
42. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 1998 50 : 265 70.
43. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci. 2004 25 : 430 6.
44. Lugnier C. Cyclic nucleotide phosphodi-esterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006 109 : 366 8.
45. Yoon SW, Goh SH, Chun JS, Cho EW, Lee MK, Kim KL, Kim JJ, Kim CJ, Poo H. Alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways. J Biol Chem. 2003 278 : 32914 20.
46. Taylor AW. The immunomodulating neuropeptide alpha-melanocyte-stimu- lating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol. 2005 162 : 43 50.
47. Sarkar A, Sreenivasan Y, Manna SK. Alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced biological responses by downregulating CD14 from macrophages. FEBS Lett. 2003 553 : 286 94.
48. Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, Garcia-Gómez M, Leceta J, Juarranz Y. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol. 2005 78 : 491 502.
49. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP. Shedding of membrane-bound CD14 from lipopolysac-charide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Neuroimmunol. 1999 99 : 61 71.
50. Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotox-emia by downregulating the inflammatory response. Am J Pathol. 2006 168 : 1921 30.
51. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M. Cortistatin, a new anti-inflammatory peptide with therapeutic action in lethal endotoxemia. J Exp Med. 2006 203 : 463 71.
52. Chiao H, Foster S, Thomas R, Lipton J, Star RA. Alpha-melanocyte- stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest. 1996 97 : 2038 44.
53. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, Gomariz RP. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J Immunol. 1999 162 : 1200 5.
54. Wu R. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res. 2005 68 : 318 26.
55. Tuncel N, Tore F, Sahinturk V, Ak D, Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides. 2000 21 : 81 9.
56. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001 7 : 563 8.
57. Gonzalez-Rey E, Chorny A, Varela N, Del Moral, RG, Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and TH-1 responses. Ann Rheum Dis. 2007 66 : 582 8.
58. Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation. 1994 1 : 28 32.
59. Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by downregulating inflammatory and Th1 response and inducing regulatory T cells. Arthritis Rheum. 2007 56 : 531 43.
60. Gonzalez-Rey E, Chorny A, O'Valle F, Delgado M. Adrenomedullin protects from experimental arthritis by downregulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol. 2007 170 : 263 71.
61. Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M. Cortistatin, a new anti-inflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci USA. 2006 103 : 4228 33.
62. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut. 2006 55 : 824 32.
63. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003 124 : 961 71.
64. Rajora N, Boccoli G, Catania A, Lipton JM. Alpha-MSH modulates experimental inflammatory bowel disease. Peptides. 1997 18 : 381 5.
65. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology. 2006 130 : 1707 20.
66. Herrera JL, Fernandez-Montesinos R, Gonzalez-Rey E, Delgado M, Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann NY Acad Sci. 2006 1070 : 337 41.
67. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Perez Leiros C. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci. 2006 1070 : 525 30.
68. Poliak S, Mor F, Conlon P, Wong T, Ling N, Rivier J, Vale W, Steinman L. Stress and autoimmunity: the neuropeptides cor-ticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J Immunol. 1997 158 : 5751 6.
69. Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol. 2006 26 : 430 7.
70. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am J Pathol. 2006 168 : 1179 88.
71. Lodde BM, Mineshiba F, Wang J, Cotrim AP Afione S, Tak PP Baum BJ. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjörgre's disease. Ann Rheum Dis. 2006 65 : 195 200.
72. Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT Nawata H. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas. 2005 30 : 62 70.
73. Dembinski A, Warzecha Z, Ceranowicz P, Tomaszewska R, Stachura J, Konturek SJ, Konturek PC. Ghrelin attenuates the development of acute pancreatitis in rat. J Physiol Pharmacol. 2003 54 : 561 73.
74. Nishida T, Taylor AW. Specific aqueous humor factors induce activation of regulatory T cells. Invest Ophthalmol Vis Sci 1999 40 : 2268 74.
75. Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol. 2004 122 : 1179 84.
76. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutic approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des. 2007 13 : 1113 39.
77. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFN-γ synthesis by T cells. J Neuroimmunol. 1999 96 : 167 81.
78. Hernanz A, Tato E, De La Fuente M, De Miguel E, Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroummunol. 1997 71 : 25 30.
79. Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, Gomariz RP. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF production by macrophages: in vitro and in vivo studies. J Immunol. 1999 162 : 2358 67.
80. Delgado R, Carlin A, Airaghi L, Demitri MT, Meda L, Galimberti D, Baron P, Lipton JM, Catania A. Melanocortin peptides inhibit production of proinflam-matory cytokines and nitric oxide by activated microglia. J Leukoc Biol. 1998 63 : 740 5.
81. Delgado M, Jonakait GM, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia. 2002 39 : 148 61.
82. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of proinflammatory mediators by activated microglia by down-regulating NFkB. J Leukoc Biol. 2003 73 : 155 64.
83. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998 63 : 591 601.
84. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and IFN regulatory factor 1 activation. J Immunol. 1999 162 : 4685 96.
85. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P. Corticosteroid-independ-ent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol Endocrinol Metab. 1998 275 : E757 62.
86. Delgado M, Ganea D. Inhibition of endo-toxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol. 2001 167 : 966 75.
87. Wang MJ, Lin SZ, Kuo JS, Hang HY, Tzeng SF, Liao CH, Chen DC, Chen WF. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol. 2007 179 : 6204 14.
88. Delgado M, Gonzalez-Rey E. Vasoactive intestinal peptide inhibits cycloxygenease 2 expression in activated macrophages, microglia and dendritic cells. Brain Behav Immun. 2008 22 : 35 41.
89. Bhardwaj RS, Schwarz A, Becher E, Mahnke K, Aragane Y, Schwarz T, Luger TA. Pro-opiomelanocortin-derived pep-tides induce IL-10 production in human monocytes. J Immunol. 1996 156 : 2517 21.
90. Delgado M, Muñoz-Ehías EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol. 1999 162 : 1707 16.
91. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann NY Acad Sci. 2003 994 : 133 40.
92. + T cells. J Leukoc Biol. 2004 75 : 1122 30.
93. Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating the secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol. 2008 172 : 1297 307.
94. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol. 2008 180 : 8369 77.
95. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A, Margioris AN. Urocortin 1 and urocortin 2 induce macrophage apop-tosis via CRFR2. FEBS Lett. 2005 579 : 4259 64.
96. Miksa M, Wu R, Cui W, Dong W, Das P, Simms HH, Ravikuman TS, Wang P. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome prolif-erator-activating receptor-γ. J Immunol. 2007 179 : 6263 72.
97. Delgado M, Leceta J, Gomariz RP Ganea D. VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression. J Immunol. 1999 163 : 3629 35.
98. Jiang X, Jing H, Ganea D. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol. 2002 133 : 81 94.
99. Delgado M, Gonzalez-Rey E, Ganea D. VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J. 2004 18 : 1453 5.
100. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol. 2006 176 : 97 110.
101. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. 2002 16 : 1844 6.
102. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol. 2004 172 : 7289 96.
103. + regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum. 2006 54 : 864 76.
104. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol. 2006 36 : 318 26.
105. + regulatory T cells in vivo. J Leukoc Biol. 2005 78 : 1327 38.
106. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA. 2005 102 : 13562 7.
107. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005 175 : 7311 24.
108. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006 107 : 3632 8.
109. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH pep-tides. J Leukoc Biol. 2000 67 : 233 9.
110. Allaker R P, Zihni C, Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol Med Microbiol. 1999 23 : 289 93.
111. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, Brabet P, Leceta J, Gomariz RP. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypep-tide receptor. Proc Natl Acad Sci USA. 2002 99 : 1053 8.
112. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI. Mice lacking the VIP gene show airway hyperre-sponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol. 2006 291 : 880 6.
113. Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible VIP receptor. FASEB J. 2001 15 : 2489 96.
114. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF, Harmar AJ. Enhanced delayed-type hypersensitiv-ity and diminished immediate-type hyper-sensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc Natl Acad Sci USA. 2001 98 : 13854 9.
115. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol. 2003 170 : 308 14.
116. Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid syn-ovial fibroblasts. Arthritis Rheum. 2008 58 : 1086 95.
117. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J. Genetic association of vasoactive intestinal peptide with rheumatoid arthritis. Altered expression and signal in immune cells. Arthritis Rheum. 2008 58 : 1010 9.
118. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol. 2006 18 : 1691 700.
119. Bangale Y, Karle S, Planque S, Zhou YX, Taguchi H, Nishiyama Y, Li L, Kalaga R, Paul S. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J. 2003 17 : 628 35.
120. Moncada S, Ferreira SH, Vane JR. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature. 1973 246 : 217 9.
121. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001 208 : 15 23.
122. Levy BD, Clish DB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001 2 : 612 9.
123. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins. 1997 53 : 107 37.
124. Serhan CN, Takano T, Clish CB, Gronert K, Petasis N. Aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogs inhibit neutrophil-mediated changes in vascular permeability. Adv Exp Med Biol. 1999 469 : 287 93.
125. Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stim-ulated interactions of human neutrophils and endothelial cells. J Immunol. 1996 156 : 2264 72.
126. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactiva-tion by dehydrogenation and reduction. J Exp Med. 1996 183 : 137 46.
127. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem. 1997 272 : 6972 8.
128. József L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxyni-trite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA. 2002 99 : 13266 71.
129. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 2000 164 : 1663 7.
130. Mitchell S, Thomas G, Harvey K, Cottell D, Revllle K, Berlasconl G, Petasls NA, Erwlg L, Rees AJ, Savlll J, Brady HR, Godson C. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 2002 13 : 2497 507.
131. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007 25 : 101 37.
132. Yacoubian S, Serhan CN. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol. 2007 3 : 570 9.
133. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem. 1929 82 : 345 67.
134. Camuesco D, Galvez J, Nieto A, Comalada M, Rodriguez-Cabezas ME, Concha A, Xaus J, Zarzuelo A. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr. 2005 135 : 687 94.
135. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs. Circulation. 1999 99 : 2452 7.
136. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastroginseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F, GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 105 : 1897 1903.
137. Holub DJ, Holub BJ. Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem. 2004 263 : 217 25.
138. Engler MM, Engler MB, Malloy M, Chiu E, Besio D, Paul S, Stuehlinger M, Morrow JD, Ridker PM, Rifai N, Mietus-Snyder M. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther 2004 42 : 672 9.
139. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr., Frautschy SA, Cole GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005 25 : 3032 40.
140. Serhan CN, Clish CB, Brannon J, Colgan S P, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med. 2000 192 : 1197 204.
141. Serhan CN, Hong S, Gronert K, Colgan S P, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med. 2002 196, 1025 37.
142. Hong S, Gronert K, Devchand P, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: auta-coids in anti-inflammation. J Biol Chem. 2003 278 : 14677 87.
143. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and proinflammatory gene expression. J Biol Chem. 2003 278 : 43807 17.
144. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived doco -satriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA. 2004 101 : 8491 6.
145. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. A role for docosahexaenoic acid-derived neuropro-tectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005 115 : 2774 83.
146. Serhan CN, Gorlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP, Petasis NA. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol. 2006 176 : 1848 59.
147. Arita, M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005 201 : 713 22.
148. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol. 2005 174 : 4345 55.
149. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteo-clast- mediated bone destruction in peri-odontitis. FASEB J. 2006 20 : 401 3.
150. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 2007 21 : 3162 70.
151. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA. 2005 102 : 7671 6.
152. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007 178 : 3912 7.
153. Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol. 2006 177 : 5902 11.
154. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem. 2005 280 : 15267 78.
155. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 2007 178 : 496 502.
156. Ariel A, Li PL, Wang W, Tang WX, Fredman G, Hong S, Gotlinger KH, Serhan CN. The docosatriene protectin D1 is produced by TH2 skewing and promotes human cell apoptosis via lipid raft clustering. J Biol Chem. 2005 280 : 43079 86.
157. Arrington JL, Chapkin RS, Switzer KC, Morris JS, McMurray DN. Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation. Clin Exp Immunol. 2001 125 : 499 507.
158. Chapkin RS, Arrington JL, Apanasovich TV, Carroll RJ, McMurray DN. Dietary n-3 PUFA affect TcR-mediated activation of purified murine T cells and accessory cell function in co-cultures. Clin Exp Immunol. 2002 130 : 12 8.
159. Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, Luster AD, Serhan CN. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol. 2006 7 : 1209 16.
160. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007 447 : 869 74.
161. Ueda S, Nishio K, Minamino N, Kubo A, Akai Y, Kangawa K, Matsuo H, Fujimura Y, Yoshioka A, Masui K, Doi N, Murao Y, Miyamoto S. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med. 1999 160 : 132 6.
162. Brandtzaeg P, Oktedalen O, Kierulf P, Opstad PK. Elevated VIP and endotoxin plasma levels in human gram-negative septic shock. Regul Pept. 1989 24 : 37 44.
163. Delgado M, Abad C, Martinez C, Lecta J, Gomariz RP. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med. 2002 80 : 16 24.
164. Yudoh K, Matsuno H, Kimura T. Plasma adrenomedullin in rheumatoid arthritis compared with other rheumatic diseases. Arthritis Rheum. 1999 42 : 1297 8.
165. Torpy DJ, Webster EL, Zachman EK, Aguilera G, Chrousos GP. Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Neuroimmunomodulation. 1999 6 : 182 6.
166. Peracchi M, Bardella MT, Caprioli F, Massironi S, Conte D, Valenti L, Ronchi C, Beck-Peccoz P, Arosio M, Piodi L. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut. 2006 55 : 432 3.
167. Serhan NC, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005 : 6 : 1191 7.
168. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000 101 : 498 503.
169. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci. 2005 109 : 381 8.
170. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003 111 : 1339 46.
171. Broglio F, Benso A, Gottero C, Prodam F, Gauna C, Filtri L, Arvat E, Van Der Lely AJ, Deghenghi R, Ghigo E. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab. 2002 87 : 4829 32.
172. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004 4 : 24 34.
173. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006 108 : 1435 40.
174. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology. 2006 131 : 1799 1811.
175. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ. Development and clinical application of peptide-based radio-pharmaceuticals. Curr Pharm Des. 2004 10 : 2951 63.
176. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers. 1995 37 : 57 66.
177. Onyuksel H, Ikezaki H, Patel M, Gao XP, Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res. 1999 16 : 155 60.
178. Sethi V, Onyuksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 2005 391 : 377 95.
179. Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apop-tosis after ischemia and reperfusion. Am J Physiol Heart Cir Physiol. 2003 285 : H1506 14.
180. Delgado M, Toscano MG, Benabdellah K, Cobo M, O'Valle F, Gonzalez-Rey E, Martin F. In vivo delivery of lentiviral vectors expressing vasoactive intestinal pep-tide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum. 2008 58 : 1026 37.
181. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther. 2005 7 : 253 69.
182. Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther. 2003 5 : 317 28.
183. Moffatt, JD, Lever, R. and Page, CP Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. FASEB J. 2006 20 : 1877 9.
184. Blakeney JS, Fairlie D P. Nonpeptide lig-ands that target peptide-activated GPCRs in inflammation. Curr Med Chem. 2005 12 : 3027 42.
185. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Disc. 2003 2 : 999 1017.
186. Bürli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, Adlam M, Plant MH, Wong M, McElvain M, Regal K, Viswanadhan VN, Tagari P, Hungate R. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 16 : 3713 8.
187. Kim Y, Lee BD, Bae YS, Lee T, Suh PG, Ryu SH. Pituitary adenylate cyclase-acti-vating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. J Immunol. 2006 176 : 2969 75.
188. El Zein N, Badran B, Sariban E. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPLR1. J Leukoc Biol. 2008 83 : 972 81.